develop
antivir
therapeut
emphas
minim
effect
dose
maxim
toxic
dose
first
cell
cultur
later
anim
model
longterm
success
antivir
therapeut
determin
efficaci
also
durat
time
requir
resist
evolv
develop
microfluid
devic
compris
well
well
contain
microstructur
captur
singl
cell
use
devic
character
enteroviru
inhibitor
distinct
mechan
action
contrast
popul
method
singlecel
analysi
reveal
class
inhibitor
interfer
viral
infect
cycl
manner
copyright
holder
preprint
peerreview
authorfund
predict
likelihood
evolut
resist
gener
take
year
effort
follow
compound
discoveri
part
studi
evalu
pv
infect
dynam
singlecel
level
observ
chaintermin
antivir
ribonucleotid
select
elimin
mostfit
member
viral
popul
guo
et
al
class
antivir
agent
alway
tout
high
barrier
resist
jordheim
et
al
typic
explan
high
barrier
amino
acid
substitut
activ
site
viral
rna
polymeras
confer
resist
antivir
ribonucleosid
also
impair
specif
andor
effici
incorpor
natur
ribonucleotid
carrol
et
al
elimin
mostfit
member
viral
popul
antivir
agent
requir
resist
emerg
surviv
lowfit
member
popul
would
ultim
requir
restor
fit
popul
surviv
myriad
mechan
host
restrict
andino
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
domingo
restor
fit
may
insurmount
barrier
preclud
develop
resist
chaintermin
antivir
ribonucleotid
studi
design
determin
extent
singlecel
analysi
antivir
agent
contribut
understand
antivir
therapeut
rel
tradit
approach
describ
microfluid
devic
use
produc
complet
respons
curv
use
devic
compar
three
mechanisticallydistinct
class
antivir
agent
pv
polymeras
inhibitor
pv
proteas
inhibitor
rupintrivir
two
inhibitor
geldanamycin
ga
ganetespib
gs
find
singlecel
analysi
distinguish
class
inhibitor
suggest
addit
singlecel
analysi
exist
paradigm
preclin
develop
antivir
therapi
may
potenti
identifi
lead
limit
potenti
develop
resist
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
devic
singlecel
analysi
activ
antivir
agent
initi
foray
singlecel
analysi
pv
infect
dynam
use
cell
densiti
control
singlecel
occup
well
microfluid
devic
guo
et
al
mean
practic
well
empti
reduc
number
event
monitor
mere
factor
two
take
us
number
event
requir
statist
analysi
data
acquisit
respons
curv
therefor
imposs
use
firstgener
devic
address
problem
creat
multilay
devic
previous
describ
fig
guo
et
al
ad
trap
structur
channel
layer
devic
fig
posit
trap
structur
guid
simul
fig
lead
placement
trap
structur
rear
wall
well
fig
devic
contain
five
independ
zone
contain
well
total
well
devic
mount
easili
stage
microscop
fig
devic
crosssect
shown
fig
singlecel
occup
devic
sensit
width
channel
use
load
fig
cell
densiti
fig
maximum
occup
near
fig
condit
inhibitor
reduc
infect
infect
cell
observ
use
devic
number
event
enough
statist
analysi
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
authorfund
copyright
holder
preprint
peerreview
authorfund
densiti
cellsml
load
microfluid
devic
well
monitor
egfp
fluoresc
everi
min
h
period
give
rise
popul
time
cours
exhibit
substanti
betweencel
variabl
fig
plot
percentag
infect
cell
function
drug
concentr
fit
hyperbola
obtain
valu
valu
case
concentr
greater
exhibit
toxic
stuyver
et
al
therefor
data
fit
hyperbola
fig
clear
experi
howev
approach
sensit
enough
acquir
data
complet
doserespons
analysi
fig
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
major
advantag
singlecel
platform
effect
drug
viabl
popul
determin
analyz
singlecel
data
use
five
phenomenolog
paramet
extract
time
cours
fig
paramet
maximum
fluoresc
observ
correl
yield
genom
rna
slope
time
maximum
fluoresc
correl
replic
speed
infect
time
first
approxim
time
take
infect
go
start
finish
akin
viru
sensit
unexpect
could
easili
ration
notion
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
authorfund
concentr
observ
statist
signific
differ
compar
control
paramet
maximum
fig
slope
fig
infect
time
fig
start
point
fig
midpoint
fig
outcom
rupintrivir
clearli
distinct
cmea
conclud
antivir
agent
interfer
viral
popul
manner
stage
lifecycl
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
infect
establish
valu
nm
fig
earlier
studi
observ
impact
ga
prior
viru
assembl
howev
possibl
reduct
magnitud
shown
would
conceal
experiment
error
geller
et
al
infect
monitor
egfp
requir
viru
entri
genom
replic
genom
translat
interfer
step
would
lead
reduct
number
egfpposit
cell
clear
howev
translat
fold
egfp
alter
presenc
highest
concentr
ga
use
experi
fig
analysi
singlecel
data
present
tabl
mean
distribut
valu
maximum
paramet
chang
presenc
ga
fig
contrast
inhibitor
target
viral
protein
observ
statist
signific
differ
distribut
valu
infectiontim
paramet
concentr
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
depend
fig
statist
signific
differ
mean
distribut
remain
paramet
observ
concentr
correspond
fig
third
signatur
antivir
action
therefor
reveal
ga
given
interest
use
inhibitor
therapeut
cancer
varieti
compound
exist
hwang
et
al
sidera
patsavoudi
exampl
ganetespib
gs
inhibitor
differ
ga
substanti
chemic
structur
compar
inset
fig
fig
higher
affin
ga
ga
fig
case
clear
mechanist
ident
compound
yield
ident
signatur
singlecel
level
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
authorfund
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
evalu
antivir
drug
combin
longterm
util
antivir
therapi
determin
part
time
requir
resist
mutant
emerg
one
approach
delay
even
elimin
emerg
drugresist
mutant
use
antivir
combin
dun
et
al
hofmann
et
al
often
evalu
abil
two
drug
exhibit
greater
efficaci
synergi
prevent
infect
combin
observ
either
drug
use
alon
evalu
abil
synerg
ga
treat
cell
concentr
one
valu
fig
absenc
drug
cell
devic
infect
number
reduc
presenc
ga
combin
thereof
respect
base
observ
alon
conclus
would
combin
antivir
agent
even
addit
analysi
entir
singlecel
dataset
present
tabl
exhibit
substanti
antivir
effect
rel
control
compar
combin
alon
observ
statist
signific
differ
paramet
fig
singlecel
analysi
therefor
abil
reveal
efficaci
drug
combin
mask
popul
level
perform
compar
experi
gs
reach
conclus
fig
tabl
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
three
class
antipv
drug
reveal
three
uniqu
signatur
base
chang
phenomenolog
paramet
use
describ
infect
dynam
reason
pca
might
provid
even
robust
approach
compar
dataset
use
five
paramet
shown
fig
pca
resolv
class
inhibitor
well
outcom
absenc
drug
importantli
mechanist
relat
chemic
distinct
inhibitor
cluster
pca
see
ga
gs
fig
conclud
singlecel
analysi
antivir
therapeut
provid
inform
efficaci
drug
also
inform
mechan
action
experiment
paradigm
transform
impact
drugdevelop
process
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
authorfund
firstgener
microfluid
devic
onchip
investig
viral
infect
dynam
reli
cell
densiti
mechan
achiev
isol
singl
cell
well
devic
approach
leav
well
devic
empti
guo
et
al
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
redesign
devic
add
physic
celltrap
structur
well
outcom
abil
achiev
singlecel
occup
well
devic
fig
enhanc
occup
enabl
complet
character
antivir
therapeut
permit
acquisit
complet
doserespons
curv
eg
fig
three
class
antivir
therapeut
chosen
target
viral
polymeras
methyladenosin
mea
fig
viral
proteas
rupintrivir
fig
host
factor
geldanamycin
ga
fig
ganetespib
gs
fig
dataanalysi
pipelin
emphas
five
phenomenolog
paramet
correl
tradit
paramet
assess
viral
lifecycl
major
find
studi
class
antivir
therapeut
exhibit
uniqu
signatur
respect
five
phenomenolog
paramet
measur
much
possibl
use
princip
compon
analysi
pca
stratifi
differ
therapeut
class
fig
importantli
ga
gs
overlap
pca
despit
substanti
differ
structur
efficaci
fig
knowledg
studi
repres
first
analysi
rang
antivir
therapeut
viral
infect
dynam
singlecel
level
resolut
afford
approach
unpreced
compar
cellbas
approach
provid
measur
efficaci
given
substanti
effort
requir
go
compound
mechan
use
tradit
experiment
paradigm
abil
singlecel
analysi
inform
mechan
make
approach
welcom
addit
drug
discoveri
develop
toolbox
uncommon
analogu
synthes
develop
process
lose
specif
even
function
differ
mechan
action
singlecel
analysi
potenti
reveal
chang
start
analysi
instead
much
much
later
develop
process
final
although
use
antivir
agent
demonstr
power
singlecel
analysi
use
technolog
approach
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
applic
discoveri
develop
class
therapeut
assess
cell
cultur
